TP53 and myelodysplastic syndrome: In a phase 1b/2 trial, the combination of eprenetapopt and azacitidine was well tolerated in patients with TP53-mutated MDS or AML with 20–30% bone marrow blasts; median overall survival was 10.8 months, and the overall response rate was 71% [111].